{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:02:21Z","timestamp":1780408941969,"version":"3.54.1"},"reference-count":8,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,6,3]],"date-time":"2015-06-03T00:00:00Z","timestamp":1433289600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The only clinically available cephalosporin with in\u00a0vivo and in\u00a0vitro activity against methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic> is ceftaroline, which is approved for the treatment of soft tissue infection and community\u2010acquired pneumonia in doses of 600\u00a0mg intravenously every 12\u00a0hours for 2\u00a0weeks or less. However, many clinicians use ceftaroline to treat more serious infections and dose more frequently (every 8\u00a0hours) for longer periods of time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective medication safety assessment was performed at two centers where agranulocytosis was observed in four patients (two at each center) who were treated with ceftaroline. The cases were reviewed by the treating physicians for common features, and the frequency of agranulocytosis was calculated based on the total number of treated patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We report four cases of agranulocytosis associated with ceftaroline use, highlighted by prolonged use (more than 14\u00a0days) and 8\u2010hour dosing intervals or 12\u2010hour dosing intervals with concomitant clindamycin therapy. When ceftaroline (600\u00a0mg every 12\u00a0hours) and clindamycin (900\u00a0mg every 8\u00a0hours) were coadministered for more than 2\u00a0weeks, the frequency of agranulocytosis was 18% (2 of 18 patients treated). When ceftaroline alone was administered for more than 2\u00a0weeks at 600\u00a0mg every 8\u00a0hours, agranulocytosis occurred in 5.4% (2 of 37 treated patients). No cases of ceftaroline\u2010related agranulocytosis were seen that did not have these features. In these patients, granulocyte\u2010colony stimulating factor therapy usually resulted in rapid myeloid recovery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Clinicians should have a heightened awareness of agranulocytosis when using ceftaroline in such settings and monitor complete blood counts at least once\/week.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.1596","type":"journal-article","created":{"date-parts":[[2015,6,3]],"date-time":"2015-06-03T04:42:09Z","timestamp":1433306529000},"page":"608-612","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Agranulocytosis with Ceftaroline High\u2010Dose Monotherapy or Combination Therapy with Clindamycin"],"prefix":"10.1002","volume":"35","author":[{"given":"Neilmegh L.","family":"Varada","sequence":"first","affiliation":[{"name":"Department of Health and Human Services Yakama Indian Health Clinic Toppenish Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sakoulas","sequence":"additional","affiliation":[{"name":"Department of Pediatrics University of California San Diego School of Medicine La Jolla California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lani R.","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Trios Health Kennewick Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Chua","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Trios Health Kennewick Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,3]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp100181"},{"key":"e_1_2_5_3_1","unstructured":"Forest Laboratories.Ceftaroline package insert forest laboratories. Available fromhttp:\/\/www.frx.com\/pi\/teflaro_pi.pdf. Accessed December 5 2014."},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/152.1.90"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.05.061"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130474"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12062"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2007.01408.x"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1596","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:58:38Z","timestamp":1761051518000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1002\/phar.1596"],"URL":"https:\/\/doi.org\/10.1002\/phar.1596","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"2015-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}